Table 1.
Baseline characteristics
| Characteristic | N = 440 |
|---|---|
| Age, years, mean (SD) | 45.3 (14.3) |
| ≥65 years, n (%) | 48 (10.9) |
| Male, n (%) | 312 (70.9) |
| Geographic descent, n (%) | |
| Europe | 170 (38.6) |
| Middle East | 21 (4.8) |
| Asia Pacific | 101 (23.0) |
| North Africa | 44 (10.0) |
| Sub-Saharan Africa | 87 (19.8) |
| North and South America | 11 (2.5) |
| Unknown | 6 (1.4) |
| Genotype, n (%) | |
| A | 4 (0.9) |
| B | 5 (1.1) |
| C | 7 (1.6) |
| D | 9 (2.0) |
| E | 5 (1.1) |
| Missing | 410 (93.2) |
| Patients with cirrhosis, n (%)a | 68 (15.5) |
| Liver biopsy performed, n (%) | 298 (67.7) |
| Fibrosis stage (METAVIR), n (%) | |
| F0–F1 | 105 (36.5) |
| F2 | 88 (30.6) |
| F3 | 53 (18.4) |
| F4 | 42 (14.6) |
| Missing | 10 |
| Comorbidities, n (%)b | |
| Hypertension | 48 (10.9) |
| Diabetes mellitus | 40 (9.1) |
| Cardiovascular disease | 16 (3.6) |
| Rheumatic disease | 15 (3.4) |
| Renal insufficiency/dysfunction | 14 (3.2) |
| Malignant disease | 10 (2.3) |
| Neuropsychiatric disease | 9 (2.1) |
| Other | 104 (23.6) |
SD standard deviation
aHistory of cirrhosis as defined by the investigator; method not further specified
bWhere reported (n = 170). Multiple comorbidities were possible